New Classes of Antiretrovirals: The Clinical Role of Integrase Inhibitors and Entry Inhibitors

Sunday, September 16

Room: E450A
Reception Time: 5:00 p.m. – 5:30 p.m.
Symposium Time: 5:30 p.m. – 7:30 p.m.

Supported by an Educational Grant from Merck & Co, Inc.

Welcome and Introduction
Joseph J. Eron, Jr., MD
Professor of Medicine
University of North Carolina School of Medicine
Director, AIDS Clinical Trial Unit
Associate Director, Clinical Research Unit
University of North Carolina
Chapel Hill, North Carolina

New Classes of Antiretrovirals and How They Work
Daniel R. Kuritzkes, MD
Director of AIDS Research
Brigham & Women's Hospital
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

How, When, and Why to Use Novel Agents
Eric S. Daar, MD
Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

Interactive Case Studies: Use of Agents in New Antiretroviral Classes in Treatment-Experienced Patients
Eric S. Daar, MD
Daniel R. Kuritzkes, MD

Symposium Registration Information:
On-site registration will be accommodated as space permits.

Updated as of: August 26, 2007